- Home
- OTLK vs SCOR Comparison
OTLK vs SCOR Comparison
Compare OTLK & SCOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | SCOR |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.8M | 32.8M |
| IPO Year | 2016 | 2007 |
Fundamental Metrics
Financial Performance| Metric | OTLK | SCOR |
|---|---|---|
| Price | $2.06 | $6.71 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.25 | N/A |
| AVG Volume (30 Days) | ★ 5.5M | 13.6K |
| Earning Date | 12-26-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,505,322.00 | ★ $358,940,000.00 |
| Revenue This Year | N/A | $2.01 |
| Revenue Next Year | $342.80 | $1.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $0.79 | $4.39 |
| 52 Week High | $3.39 | $10.18 |
Technical Indicators
Market Signals| Indicator | OTLK | SCOR |
|---|---|---|
| Relative Strength Index (RSI) | 69.44 | 47.21 |
| Support Level | $1.51 | $6.40 |
| Resistance Level | $2.10 | $7.08 |
| Average True Range (ATR) | 0.20 | 0.39 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 93.22 | 61.00 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.